TKMR Share Price

Open 3.25 Change Price %
High 3.35 1 Day 0.05 1.54
Low 3.20 1 Week 0.15 4.76
Close 3.30 1 Month 0.63 23.60
Volume 207662 1 Year -0.64 -16.24
52 Week High 5.48
52 Week Low 2.35
TKMR Important Levels
Resistance 2 3.44
Resistance 1 3.38
Pivot 3.28
Support 1 3.22
Support 2 3.16
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
FTR 2.02 2.02%
FTR 2.02 2.02%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
VALV 0.04 100.00%
PTSX 0.21 90.91%
LOCM 0.09 50.00%
QKLS 0.15 50.00%
PFMT 2.41 31.69%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)

TKMR Technical Analysis 2
As on 29th Mar 2017 TKMR Share Price closed @ 3.30 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.38 & Strong Buy for SHORT-TERM with Stoploss of 2.77 we also expect STOCK to react on Following IMPORTANT LEVELS.
TKMR Target for March
1st Target up-side 2.89
2nd Target up-side 3.04
3rd Target up-side 3.19
1st Target down-side 2.45
2nd Target down-side 2.3
3rd Target down-side 2.15
TKMR Other Details
Segment EQ
Market Capital 59253228.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
TKMR Address
TKMR
N/A
TKMR Latest News
Arbutus Biopharma Corp (ABUS) Receives $6.50 Average Price Target from Analysts   BNB Daily (blog)   - 29th Mar 17
Arbutus Biopharma Corp (ABUS) Earns Outperform Rating from Wedbush   BNB Daily (blog)   - 27th Mar 17
Form 8-K Arbutus Biopharma Corp For: Mar 23   StreetInsider.com   - 24th Mar 17
Analyst Activity – Wedbush Lowers Its Price Target On Arbutus Biopharma Corp ...   Market Exclusive   - 23rd Mar 17
Arbutus Biopharma and Alexion in new licensing deal   Seeking Alpha   - 17th Mar 17
BRIEF-Arbutus Biopharma Corp files for non-timely 10-K   Reuters   - 17th Mar 17
Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race   Seeking Alpha   - 18th Nov 16
Arbutus Biopharma Corp. ABUS (US: Nasdaq)   Wall Street Journal   - 07th Aug 15
Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company   GlobeNewswire (press release)   - 20th Jul 15
Arbutus Biopharma Corp.   MarketWatch   - 29th Dec 13
Interactive Technical Analysis Chart Tekmira Pharmaceuticals Corp ( TKMR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Tekmira Pharmaceuticals Corp
TKMR Business Profile
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.